ArticleJournal of microbiology (Seoul, Korea)2024
Lactobacillus acidophilus KBL409 Ameliorates Atopic Dermatitis in a Mouse Model.
Article in Journal of microbiology (Seoul, Korea), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 14 citations in OpenAlex.
- Oral Administration of Lactiplantibacillus plantarum KBL396 Regulates Serum 5-Hydroxytryptamine and Gut Microbiota: Evidence from a Preclinical Mouse Model and a Randomized Controlled Human Trial.Probiotics and antimicrobial proteins · 2026Trial
- Lactobacillus gasseri alleviates type 2 diabetes via modulation of gut microbiota-host metabolic networks.Journal of endocrinological investigation · 2026Article
- Gut-Brain-Skin Axis: From Mechanistic Insights to Translational Applications in Neurocosmetics.Dermatology and therapy · 2026Review
- Lactobacilli Mitigate Gut Inflammation by Modulating T-Helper/T-Regulatory Cells and Suppressing Signaling Pathways in Food-Derived Models.Probiotics and antimicrobial proteins · 2026Review
- Therapeutic Potential of SpecificNutrients · 2026Article
- High-salt diet promotes atopic dermatitis by partially enhancing intestinal SGK1/ENaC signaling and destroying gutFrontiers in cellular and infection microbiology · 2026Article
- Targeting polymicrobial skin infections in atopic dermatitis: role ofFrontiers in microbiology · 2026Article
- Limosilactobacillus fermentum KBL674 Alleviates Vaginal Candidiasis.Probiotics and antimicrobial proteins · 2025Article
- The gut-skin axis: a bi-directional, microbiota-driven relationship with therapeutic potential.Gut microbes · 2025Review
- Lactobacillus crispatus KBL693 alleviates atopic dermatitis symptoms through immune modulation.Journal of microbiology (Seoul, Korea) · 2025Article
- Microbiota Modulation as an Approach to Prevent the Use of Antimicrobials Associated with Canine Atopic Dermatitis.Biomedicines · 2025Review
- Nanoencapsulation of Biotics: Feasibility to Enhance Stability and Delivery for Improved Gut Health.Pharmaceutics · 2025Review
- Article
- Probiotics ameliorate atopic dermatitis by modulating the dysbiosis of the gut microbiota in dogs.BMC microbiology · 2025Article
- Innovative microbial strategies in atopic dermatitis.Frontiers in immunology · 2025Review
- The Skin Histopathology of Pro- and Parabiotics in a Mouse Model of Atopic Dermatitis.Nutrients · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 4 countries.
Funding
Abstract
Atopic dermatitis (AD) is a chronic inflammatory skin disease with repeated exacerbations of eczema and pruritus. Probiotics can prevent or treat AD appropriately via modulation of immune responses and gut microbiota. In this study, we evaluated effects of Lactobacillus acidophilus (L. acidophilus) KBL409 using a house dust mite (Dermatophagoides farinae)-induced in vivo AD model. Oral administration of L. acidophilus KBL409 significantly reduced dermatitis scores and decreased infiltration of immune cells in skin tissues. L. acidophilus KBL409 reduced in serum immunoglobulin E and mRNA levels of T helper (Th)1 (Interferon-γ), Th2 (Interleukin [IL]-4, IL-5, IL-13, and IL-31), and Th17 (IL-17A) cytokines in skin tissues. The anti-inflammatory cytokine IL-10 was increased and Foxp3 expression was up-regulated in AD-induced mice with L. acidophilus KBL409. Furthermore, L. acidophilus KBL409 significantly modulated gut microbiota and concentrations of short-chain fatty acids and amino acids, which could explain its effects on AD. Our results suggest that L. acidophilus KBL409 is the potential probiotic for AD treatment by modulating of immune responses and gut microbiota of host.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.